近日，基金经理"晒实盘"频频引发关注。 鑫元基金的基金经理刘俊文在今年4月末公开了实盘组合，最新名称为"防守反击赢"，该组合也是100%配置其管理的鑫元价值精选混合A。6月6日，刘俊文 在基金净值冲高回落时加仓30万元，随后他"晒"出实盘情况，并附文表示选择加仓"并非源于对短期行情的乐观预测，更非盲目的冲动"，而是基于对当前市 场位置的明确判断，和对自身交易模式的绝对信念。 今年一季度，刘俊文曾发文称，"我买自己管理的产品知根知底，同时也能不断提醒自己：如果做砸了就只能喝西北风了。自购让我和投资人的利益绑在一 起，通俗来讲'我们都是一条船上的人了'。"最新数据显示，截至7月11日，刘俊文的实盘组合最新资产为113.48万元，成立以来累计收益为小幅亏损约2700 元左右。 上银基金的基金经理陈博是在今年5月公开了"左手红利右手科技"的基金组合。该组合约88%仓位配置上银未来生活灵活配置混合（A/C份额合并计算），约 12%仓位配置上银鑫达灵活配置混合A，这两只基金均是他自己管理的产品，最新的操作是在7月4日新增上银未来生活灵活配置混合C份额18.26万份。截至7 月11日，该组合成立以来的收益率为9.29%，总 ...

.@ARKInvest has been wondering how much of a sleeper #Tesla’s Dojo is. Interesting perspective here.RimRunner (@samwose):@StockSavvyShay 1. Breaking Free from NvidiaTesla currently relies on Nvidia’s A100 and H100 GPUs for training its massive video-based neural networks. While powerful, these chips are general-purpose and optimized for broader markets like LLMs and gaming.Dojo 2, by contrast, is Tesla’s ...

没看错，是亿，不是百万。 这不是故事会，而是已经发生的现实。2025年6月，英伟达市值正式突破4万亿美元，成为人类历史上第一家站上这个高度的公司。不是苹果，不是微软，也 不是亚马逊，是那家曾被人当成显卡厂的公司。 你有没有认真算过，如果当年你没听家人的劝，真的冲动一把梭哈英伟达，现在会变成什么样？ 我没开玩笑，是真在算账。2019年，英伟达股价还在区区几十美元上下跳舞。那时候AI还只是个科研圈的词，芯片行业也远不如现在这样风头无两。如果 你那会儿掏出10万美元买了英伟达的股票，到今天，市值差不多是480万美元。再往前推，2009年，10万美元可以变成4650万。而如果胆子更大，在1999年 买，那现在就是4.07亿。 我昨天看到这条消息的时候，第一反应其实不是哇，而是怎么可能？我查了下数据，发现这个怎么可能的背后逻辑其实挺清楚的，甚至说得上必然。 先说个事实。 2023年5月，英伟达发布了一个季度财报，营收年增84%，利润暴增超五倍。原因就两个字：算力。当ChatGPT、Sora、Gemini成了主角，当一切从广告推荐 算法到语音翻译都要靠大模型，所有企业忽然意识到：不买英伟达的卡，你根本没资格下场。 整条人 ...

本文首发于公众号"私募排排网"。 （点击↑↑ 上图查看详情 ） 2025年上半年，A股市场在复杂多变的国内外环境中展现较强韧性，整体呈现"震荡上行、结构分化"的格局。上证指数累计上涨2.75%，深证成 指微涨0.48%，创业板指上涨0.53%，而代表小微盘的北证50指数表现最为亮眼，涨幅高达39.45%。 值得注意的是，上半年A股市场成交规模显著放大，期间A股总成交金额达到162.68万亿元，远远超过2024年同期的101万亿元，显示出 A股市 场活跃度正快速提升！ 在如火如荼的行情之下，百亿私募旗下产品又有怎样的表现？据私募排排网数据，上半年有业绩显示的百亿私募产品共有495只，上半年收益均 值达到10.18%，超额收益均值达到8.84%。虽然 百亿私募旗下产品收益整体表现亮眼，但不同策略之间却分化明显！ 其中，量化多头策略收益 均值高达18.84%，但主观多头收益均值却仅为3.32%。 | 级产品策略 | 二级产品策略 | 私募排排网有业绩显 示的产品数 | 上半年收益均值 | 上半年超额收益均值 | | --- | --- | --- | --- | --- | | | 喜你亲杀 | 194 | 18. ...

你买到的充电宝"中招"了吗？ 近期，由充电宝行业知名品牌安克、罗马仕所引发的质量风波，在消费者群体中引起了广泛关注。 3C认证证书被"暂停"、民航局禁止携带上机、罗马仕官宣停工停产6个月……随着关于充电宝安全问题的讨论在社交媒体上持续发酵，加之一系列不利消 息不断传来，无疑给消费者心中蒙上一层更深的阴影，让大家对充电宝的购买选择和日常使用变得越发谨慎。 一场由电芯材料变更所带来的产品信任危机，就此拉开充电宝行业洗牌的序幕。 超百万台充电宝被紧急召回 最近这几天，有关安克要召回充电宝产品的电话、短信齐上阵，这才让王琳知道，原来自己曾经购买过的A1642型充电宝，存在着巨大的安全隐患。 闻讯的王琳心里不禁咯噔一下，回想起自己使用这款充电宝的种种情景，即使彼时的它显得既笨重又极易发烫，但她也只是把这当成了正常现象，从日常 通勤到出差旅行，这款充电宝几乎成了她不可或缺的能量伙伴。 直到王琳按照官方提示，在召回连接中输入了自己的充电宝型号和购买信息，确认自己手里那款产品确实符合召回条件后，她的心情瞬间变得复杂起来。 产品召回流程 一方面，王琳非常庆幸，自己能够及时收到召回通知，避免了可能发生的安全事故；另一方面，王琳又 ...

医药行业观点更新&来凯医药深度汇报 20250709 莱凯医药 L1A102 在激活素受体通路上选择性更强，安全性更优，可皮 下给药。一期临床数据显示安全性良好，多剂量递增研究正在进行中， 预计 2023 年三季度读出数据（注：原文时间，需更新）。 AKT 抑制剂是癌症治疗的重要手段，AZ 公司的 Kapi 已获 FDA 批准上 市，2024 年销售额达 4.3 亿美元。莱凯医药的 AKT 抑制剂正进行乳腺 癌三期临床，计划明年上半年申报上市，早期数据显示 PFS 与 AZ 数据 相当。 创新药泡沫化问题以及中国与美国 FDA 之间的差距如何影响未来发展？ 创新药目前尚未达到真正泡沫化阶段，与几年前中国疫苗产业相比仍有较大差 距。此外，中国临床及研发效益不断提升，但与美国 FDA 之间仍未完全接轨， 这意味着中国创新药改革仍有空间和余地。临床前研发效率提升空间依然存在， 美国市场对中国产品认可度和开放程度也支撑了创新药发展的底层逻辑。因此， 布局创新药仍是值得关注的方向。 摘要 创新药市场情绪回暖，下半年 BD 事件或将增多，与 2018 年医药行业 景气度回升相似，中国创新药和药政改革成果逐步显现，但尚未达 ...

港股消费电子跟踪汇报：地平线机器人、黑芝麻智能、佑 驾创新、京东方精电 20250709 摘要 地平线机器人公司预计 2025 年营收 33 亿元人民币，2026 年 55 亿元， 2027 年 85 亿元，维持高速增长，目前市值约 900 亿港币，对应 2025 年 25 倍 PS，中阶智驾芯片出货量与新能源车企挂钩，但市场份额预期 未下降，高增长逻辑未变。 地平线高阶智驾芯片预计 2027 年贡献 30 亿营收，2028 年实现 100 亿元营收并扭亏为盈。长期来看，2030 年保守估计营收 260 亿，乐观 超过 300 亿，对应利润 80-100 亿，市值可达 2,600-3,200 亿港币。 黑芝麻智能 2025 年预计收入 8 亿元，对应 110 亿元市值约 13 倍 PS， 主要产品为 A1,000 系列智驾芯片，预计出货量大几十万片。公司正努 力切入比亚迪 TNGIC 平台，下一代智驾芯片 A2000 预计下半年定点， 明年量产。 黑芝麻智能预计 2025 年营收增速超 70%，达 8 亿元，2026-2027 年 收入预测分别为 15 亿和 22 亿，预计 2027 年盈亏平衡，实现 20 ...

Core Insights - The rise of passive investment and the popularity of ETFs have led to an increasing number of high-net-worth individual investors participating in the market through these index products [1][6] - High-net-worth individual investors are frequently appearing in the top ten holders list of newly launched ETFs, with some investing amounts exceeding 60 million yuan [2][3] - There are indications of "helping funds" where these investors may be acting as a source of initial capital for ETF launches, often through broker channels or ETF custodians [4][6] Group 1: High-Net-Worth Individual Investors - High-net-worth individual investors are increasingly visible in the top ten holders of newly launched ETFs, such as E Fund's CSI Digital Economy Theme ETF and others [2] - Notable individual investors like Lou Jianwei and Liu Xiaorong have appeared in the top ten holders of multiple ETFs, with cumulative investments nearing 60 million yuan [2][3] - Some individual investors have made substantial single investments, such as Huang Heng and Lin Zijun, with amounts reaching 20 million yuan [3] Group 2: Market Dynamics and Participation - The participation of high-net-worth individual investors in ETF launches raises questions about the motivations behind their investments, with suggestions of "helping funds" to support new ETF offerings [4][5] - The costs associated with participating in ETF launches, including subscription costs and market conditions, may deter some investors from long-term holding [4][5] - The trend indicates a shift from individual stock selection to index-based investment strategies among personal investors, reflecting a broader acceptance of ETFs for risk diversification and lower fees [6][7] Group 3: Regulatory and Market Trends - Regulatory encouragement for high-net-worth individual investors to engage more with ETFs is evident, as these investors may prefer ETFs to avoid becoming controlling shareholders in individual stocks [7] - ETF fund managers are increasingly targeting high-net-worth clients through educational events and strategy sessions to promote ETF investment [7]

Core Viewpoint - Apple is advancing its self-developed chip strategy with the upcoming launch of the iPhone 17 series, new Mac models, and Apple Watch, indicating a significant shift in its hardware differentiation and vertical integration approach [1][2]. Group 1: Chip Development - Apple is developing at least seven new chips, including A19, A19 Pro, M5, M5 Pro, a new Apple Watch chip, a second-generation 5G modem (C2), and a combined Bluetooth and Wi-Fi chip (Proxima) [1][2]. - The A19 chip will be used in the iPhone 17 Air, while the A19 Pro will be featured in the iPhone 17 Pro and Pro Max, reinforcing Apple's strategy of using differentiated processors for high-end models [1]. - The M5 and M5 Pro processors are expected to be introduced in the updated 14-inch and 16-inch MacBook Pro series following the iPhone launch, continuing Apple's chip upgrade rhythm in its laptop product line [1]. Group 2: Enhancements in Wearable Technology - The Apple Watch Series 11 is anticipated to introduce a new processor (Bora), likely based on the A18 architecture, which will enhance the watch's performance and AI capabilities, solidifying Apple's leadership in the wearable market [2]. - The integration of Bluetooth and Wi-Fi into a single chip (Proxima) is expected to improve space utilization and power management across devices [2]. Group 3: 5G Technology and Future Outlook - The second-generation 5G modem (C2) is set to replace the current C1 chip used in the iPhone 16e, with expectations for it to debut in the iPhone 17e by 2025, showcasing Apple's efforts to reduce reliance on Qualcomm and strengthen its own connectivity solutions [2]. - This chip strategy reflects Apple's ongoing commitment to vertical integration and paves the way for enhanced collaboration among diverse devices, AI applications, and integrated communication technologies [2].

Market Overview - The Shanghai Composite Index fell by 0.13% to close at 3493.05 points, with a daily high of 3512.67 points [1] - The Shenzhen Component Index decreased by 0.06% to 10581.8 points, reaching a high of 10656.58 points [1] - The ChiNext Index rose by 0.16% to close at 2184.67 points, with a peak of 2204.64 points [1] ETF Market Performance - The median return of stock ETFs was -0.14% [2] - The highest performing scale index ETF was Huatai-PB CSI A100 ETF with a return of 0.71% [2] - The top industry index ETF was E Fund CSI 300 Healthcare ETF, yielding 1.36% [2] - The best strategy index ETF was Southern S&P China A-share Large Cap Dividend Low Volatility 50 ETF, returning 0.67% [2] - The leading thematic index ETF was China Tai CSI Hong Kong-Shanghai Innovation Drug Industry ETF, achieving a return of 1.98% [2] ETF Performance Rankings - The top three ETFs by return were: - Guotai CSI Hong Kong-Shanghai Innovation Drug Industry ETF (1.98%) - Guotai CSI Film and Television Theme ETF (1.51%) - Huatai-PB CSI Hong Kong-Shanghai Innovation Drug Industry ETF (1.45%) [5] - The three ETFs with the largest declines were: - Huaan CSI Hong Kong-Shanghai Gold Industry Stock ETF (-2.25%) - Yongying CSI Hong Kong-Shanghai Gold Industry Stock ETF (-2.15%) - Huaxia CSI Fine Nonferrous Metal Industry Theme ETF (-2.13%) [6] ETF Fund Flows - The top three ETFs by inflow were: - Huaxia SSE STAR 50 ETF (inflow of 594 million) - Jiashi SSE STAR Chip ETF (inflow of 453 million) - Guolianan CSI All-Index Semiconductor Products and Equipment ETF (inflow of 346 million) [8] - The three ETFs with the largest outflows were: - E Fund ChiNext ETF (outflow of 547 million) - Huatai-PB CSI A500 ETF (outflow of 440 million) - E Fund SSE 300 ETF Initiated (outflow of 296 million) [9] ETF Margin Trading Overview - The top three ETFs by margin buying were: - Huaxia SSE STAR 50 ETF (5.91 billion) - Guolianan CSI All-Index Semiconductor Products and Equipment ETF (2.31 billion) - Guotai CSI All-Index Securities Company ETF (2.1 billion) [11] - The highest margin selling amounts were: - Huatai-PB SSE 300 ETF (22.42 million) - GF CSI 1000 ETF (14.59 million) - Southern CSI 500 ETF (7.91 million) [12] Industry Insights - Industrial trends in the innovative pharmaceutical sector remain strong, with a focus on "innovation + internationalization" as a core direction supported by policies and enhanced global competitiveness [13] - The innovative pharmaceutical supply chain is showing signs of improvement, with overseas orders and performance recovering, and domestic business demonstrating self-controllable logic [13] - The demand in the domestic market is expected to recover by 2025, with potential growth in the consumption medical field [13] - The medical device sector is also anticipated to see improvements by 2025 [13] - The innovative pharmaceutical industry is projected to reach a turning point in 2025 [14]